--- title: "Merck (MRK), Why Is Its Latest Update Raising Bigger Questions?" type: "News" locale: "en" url: "https://longbridge.com/en/news/298090109.md" description: "Merck (MRK) faces mixed signals: FDA approval of LIPFENDRA boosts optimism, yet competitive pressure on Keytruda raises concerns. While share prices have surged significantly, valuation views diverge; analyst models suggest the stock is overvalued at $150.33 versus a fair value of $136.85, whereas Simply Wall St's DCF model estimates a higher intrinsic value of $232.91, indicating potential undervaluation." datetime: "2026-09-05T04:35:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298090109.md) - [en](https://longbridge.com/en/news/298090109.md) - [zh-HK](https://longbridge.com/zh-HK/news/298090109.md) generator: "portal-rs" --- # Merck (MRK), Why Is Its Latest Update Raising Bigger Questions? Merck (MRK) is in focus after the FDA approved LIPFENDRA, the first oral PCSK9 inhibitor for hypercholesterolemia, while competitive pressure builds around its key cancer drug franchise, including potential biosimilars to Keytruda. Against that backdrop, Merck’s recent share price momentum has been strong, with a 30 day share price return of 17.14% and a year to date share price return of 41.22%. The 1 year total shareholder return of 83.40% points to sustained optimism around its pipeline and new approvals despite rising Keytruda related competition. Capitalize on the momentum around Merck and other large pharma movers by scanning our hand picked 82 resilient stocks with low risk scores, which combine resilient balance sheets with potential pipeline catalysts. After such a sharp move in Merck on fresh LIPFENDRA optimism and rising Keytruda questions, does it make more sense to lean into the momentum now, or hold out for a cleaner entry as the valuation picture comes into focus next? ## Most Popular Narrative: 9.9% Overvalued The most followed Merck valuation narrative places fair value at $136.85, compared with the last close at $150.33, which frames the recent rally against a richer pricing backdrop. > *With its acquisition and licensing strategy, Merck has nearly tripled its late-phase pipeline since 2021, which is expected to have a potential commercial opportunity of over $50 billion by the mid-2030s, driving earnings growth.* *Read the complete narrative.* Want to see what underpins that pipeline heavy story for Merck? The narrative leans on measured revenue growth, a sharp profit margin reset and a premium future earnings multiple. **Result: Fair Value of $136.85 (OVERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, Merck’s story can shift quickly if GARDASIL softness deepens or if tougher drug pricing rules and tariffs squeeze the earnings path that underpins that fair value. Find out about the key risks to this Merck narrative. ## Another View on Merck’s Valuation The analyst driven fair value for Merck points to shares being around 9.9% overvalued at $150.33 versus $136.85. Our DCF model comes to a very different conclusion. On this view, Merck at $150.33 trades well below an estimated future cash flow value of $232.91, which frames the current price as a potential discount rather than a premium. Which lens do you feel lines up better with how you see Merck’s earnings power and risks over time? Look into how the SWS DCF model arrives at its fair value. MRK Discounted Cash Flow as at Sep 2026 Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Merck for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. ## Next Steps If the mix of optimism and concern around Merck feels familiar, that is the point. You can act by carefully weighing both sides using our 2 key rewards and 5 important warning signs. ## Looking for more investment ideas beyond Merck? If Merck has your attention, do not stop here. Broaden your watchlist with other clear setups that could sharpen your overall portfolio decisions. - Spot potential value candidates early by scanning the 19 high quality undiscovered gems before they gain wider attention. - Strengthen your core holdings by checking companies on the list of solid balance sheet and fundamentals (52 results) that pair financial resilience with grounded fundamentals. - Target resilient opportunities by running through the 47 high quality undervalued stocks that combine quality metrics with pricing that may still look reasonable. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) ## Related News & Research - [Merck & Co., Inc. $MRK Stock Holdings Decreased by Secure Asset Management LLC](https://longbridge.com/en/news/297891447.md) - [Merck & Co., Inc. $MRK Shares Bought by Benjamin Edwards Inc.](https://longbridge.com/en/news/297416761.md) - [Huge Unusual Put Options Volume in Merck - Is MRK Stock Overvalued?](https://longbridge.com/en/news/296385371.md) - [Scotiabank Reaffirms Their Buy Rating on Merck & Company (MRK)](https://longbridge.com/en/news/297510077.md) - [Braun Stacey Associates Inc. Has $35.07 Million Stock Position in Merck & Co., Inc. $MRK](https://longbridge.com/en/news/297397633.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**